Literature DB >> 6130244

Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study.

R R Holman, T L Dornan, V Mayon-White, J Howard-Williams, C Orde-Peckar, L Jenkins, J Steemson, R Rolfe, B Smith, D Barbour, K McPherson, P Poon, C Rizza, J I Mann, A H Knight, A J Bron, R C Turner.   

Abstract

74 insulin-dependent diabetic patients with background retinopathy were randomised to continue with usual diabetic care (group U) or to a more intensive programme (group A) using ultralente insulin as basal cover and soluble insulin at mealtimes. Group A attended the clinic more frequently, received closer dietary supervision, and were taught home blood glucose monitoring. Group A had a significantly lower mean glycosylated haemoglobin level during the study, although the mean level also fell in group U towards the end of year 2. Renal and sensory-nerve function were significantly better preserved in group A than in group U. Significant improvements were also seen in low-density-lipoprotein-cholesterol and whole-blood low-shear viscosity. The rate of progression of retinopathy was similar in both groups. It appears that a modest improvement in diabetic control, obtainable in most clinics, has been associated with a reduction in the progression of diabetic tissue damage.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6130244     DOI: 10.1016/s0140-6736(83)92586-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

1.  Diet and diabetic retinopathy: insights from the Diabetes Control and Complications Trial (DCCT).

Authors:  David K Cundiff; Claudio R Nigg
Journal:  MedGenMed       Date:  2005-01-06

Review 2.  ACE inhibitors in the prevention and therapy of diabetic nephropathy. What is their role?

Authors:  C C Kelleher
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Mediators of diabetic neuropathy: is hyperglycemia the only culprit?

Authors:  Anna Grisold; Brian C Callaghan; Eva L Feldman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-04       Impact factor: 3.243

Review 4.  [Normoglycemia as a therapy goal in diabetes treatment--concept and realization].

Authors:  E G Siegel
Journal:  Klin Wochenschr       Date:  1990-03-16

5.  Human ultralente insulin.

Authors:  R R Holman; J Steemson; P Darling; W G Reeves; R C Turner
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-03

6.  Blood pressure and metabolic control as risk factors for nephropathy in type 1 (insulin-dependent) diabetes.

Authors:  C Hasslacher; W Stech; P Wahl; E Ritz
Journal:  Diabetologia       Date:  1985-01       Impact factor: 10.122

7.  Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.

Authors:  I G Lewin; I A O'Brien; M H Morgan; R J Corrall
Journal:  Diabetologia       Date:  1984-06       Impact factor: 10.122

8.  Peripheral nerve function in patients with painful diabetic neuropathy treated with continuous subcutaneous insulin infusion.

Authors:  F W Bertelsmann; J J Heimans; J C Van Rooy; H F Dankmeijer; S L Visser; E A Van der Veen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-10       Impact factor: 10.154

Review 9.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

10.  Influences on control in diabetes mellitus: patient, doctor, practice, or delivery of care?

Authors:  M Pringle; C Stewart-Evans; C Coupland; I Williams; S Allison; J Sterland
Journal:  BMJ       Date:  1993-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.